Top-Rated Dividend StocksTop-Rated DividendNASDAQ:RPRX Royalty Pharma (RPRX) Stock Price, News & Analysis $27.54 -0.45 (-1.61%) (As of 09/20/2024 08:54 PM ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends About Royalty Pharma Stock (NASDAQ:RPRX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Key Stats Today's Range$27.52▼$28.1750-Day Range$26.15▼$29.2752-Week Range$25.20▼$31.66Volume5.80 million shsAverage Volume2.70 million shsMarket Capitalization$16.45 billionP/E Ratio20.55Dividend Yield3.05%Price Target$42.00Consensus RatingModerate Buy Company OverviewRoyalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 commercial products and 14 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neuroscience, immunology, respiratory, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.Read More… Forget Trump and Kamala (Ad)I hope you're deleting all those emails telling you how to make "1,000% gains" from the magic "Kamala Trade". It's nonsense. No one knows what's going to happen in November.THIS CALENDAR is the only thing that matters for you and your financial health right now. Royalty Pharma Stock Analysis - MarketRank™See Top Rated MarketRank™ StocksOverall MarketRank™: 97th PercentileRoyalty Pharma scored higher than 97% of companies evaluated by MarketBeat, and ranked 37th out of 905 stocks in the finance sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.4 / 5Analyst RatingModerate Buy Consensus RatingRoyalty Pharma has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageRoyalty Pharma has only been the subject of 2 research reports in the past 90 days.Read more about Royalty Pharma's stock forecast and price target. Earnings and Valuation2.5 / 5Proj. Earnings Growth7.92% Earnings GrowthEarnings for Royalty Pharma are expected to grow by 7.92% in the coming year, from $4.04 to $4.36 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Royalty Pharma is 20.55, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 132.40.Price to Earnings Ratio vs. SectorThe P/E ratio of Royalty Pharma is 20.55, which means that it is trading at a less expensive P/E ratio than the Finance sector average P/E ratio of about 47.15.Price to Earnings Growth RatioRoyalty Pharma has a PEG Ratio of 4.17. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioRoyalty Pharma has a P/B Ratio of 1.63. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Royalty Pharma's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted3.83% of the float of Royalty Pharma has been sold short.Short Interest Ratio / Days to CoverRoyalty Pharma has a short interest ratio ("days to cover") of 5.5.Change versus previous monthShort interest in Royalty Pharma has recently increased by 2.80%, indicating that investor sentiment is decreasing. Dividend2.5 / 5Dividend StrengthModerate Dividend YieldRoyalty Pharma pays a meaningful dividend of 3.00%, higher than the bottom 25% of all stocks that pay dividends.Dividend GrowthRoyalty Pharma does not have a long track record of dividend growth.Dividend CoverageThe dividend payout ratio of Royalty Pharma is 62.69%. This payout ratio is at a healthy, sustainable level, below 75%.Dividend SustainabilityBased on earnings estimates, Royalty Pharma will have a dividend payout ratio of 19.27% next year. This indicates that Royalty Pharma will be able to sustain or increase its dividend.Read more about Royalty Pharma's dividend. Sustainability and ESG3.7 / 5Environmental Score-2.25 Percentage of Shares Shorted3.83% of the float of Royalty Pharma has been sold short.Short Interest Ratio / Days to CoverRoyalty Pharma has a short interest ratio ("days to cover") of 5.5.Change versus previous monthShort interest in Royalty Pharma has recently increased by 2.80%, indicating that investor sentiment is decreasing. News and Social Media2.8 / 5News Sentiment0.99 News SentimentRoyalty Pharma has a news sentiment score of 0.99. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.59 average news sentiment score of Finance companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Royalty Pharma this week, compared to 4 articles on an average week.Search InterestOnly 8 people have searched for RPRX on MarketBeat in the last 30 days. This is a decrease of -64% compared to the previous 30 days.MarketBeat FollowsOnly 11 people have added Royalty Pharma to their MarketBeat watchlist in the last 30 days. This is a decrease of -21% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Royalty Pharma insiders have not sold or bought any company stock.Percentage Held by Insiders18.90% of the stock of Royalty Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions54.35% of the stock of Royalty Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Royalty Pharma's insider trading history. RPRX Stock News HeadlinesStockNews.com Upgrades Royalty Pharma (NASDAQ:RPRX) to "Buy"September 19, 2024 | americanbankingnews.com3 High-Yield Dividend Stocks Down by More Than 39% to Buy Now and Hold at Least a DecadeSeptember 16, 2024 | fool.comThe election trade you can't losePolitics is an unpredictable game. But no matter what happens in the next few months... There's one thing that can't be stopped by anything: Dividends.September 23, 2024 | Investors Alley (Ad)2 Unstoppable Dividend Growth Stocks You Can Buy Now With $100September 8, 2024 | fool.comRoyalty Pharma plc's (NASDAQ:RPRX) Stock Is Rallying But Financials Look Ambiguous: Will The Momentum Continue?September 7, 2024 | finance.yahoo.comRare Disease-Focused Ascendis Pharma Stock Falls On Underwhelming Q2 Earnings, Guidance CutSeptember 4, 2024 | benzinga.comRoyalty Pharma and Ascendis Pharma Enter Into $150 Million Royalty Funding AgreementSeptember 3, 2024 | globenewswire.comRoyalty Pharma to Present at Morgan Stanley’s 22nd Annual Global Healthcare ConferenceAugust 29, 2024 | finance.yahoo.comSee More Headlines RPRX Stock Analysis - Frequently Asked Questions How have RPRX shares performed this year? Royalty Pharma's stock was trading at $28.09 at the beginning of 2024. Since then, RPRX stock has decreased by 2.0% and is now trading at $27.54. View the best growth stocks for 2024 here. How were Royalty Pharma's earnings last quarter? Royalty Pharma plc (NASDAQ:RPRX) released its earnings results on Thursday, August, 8th. The biopharmaceutical company reported $0.96 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.95 by $0.01. The biopharmaceutical company had revenue of $537 million for the quarter, compared to the consensus estimate of $600.83 million. Royalty Pharma had a trailing twelve-month return on equity of 23.61% and a net margin of 30.08%. When did Royalty Pharma IPO? Royalty Pharma (RPRX) raised $1.9 billion in an IPO on Tuesday, June 16th 2020. The company issued 70,000,000 shares at a price of $25.00-$28.00 per share. J.P. Morgan, Morgan Stanley, BofA Securities, Goldman Sachs, Citigroup and UBS Investment Bank acted as the underwriters for the IPO and Evercore ISI, Cowen and SunTrust Robinson Humphrey were co-managers. Who are Royalty Pharma's major shareholders? Royalty Pharma's top institutional shareholders include Baillie Gifford & Co. (2.74%), Swedbank AB (1.81%), New South Capital Management Inc. (0.39%) and Bank of New York Mellon Corp (0.26%). Insiders that own company stock include 1978 Sicaf Sif SA Gg, 1978 Sicaf Sif SA - Gg St Gg, Mario Germano Giuliani, Avara Management Ltd, Terrance P Coyne, James F Reddoch, Pablo G Legorreta, George W Lloyd, Marshall Urist, Rory B Riggs and Henry A Fernandez. View institutional ownership trends. How do I buy shares of Royalty Pharma? Shares of RPRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Royalty Pharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Royalty Pharma investors own include Twitter (TWTR), Bausch Health Companies (BHC), NVIDIA (NVDA), (RLYP) (RLYP), Aeterna Zentaris (AEZS), Advanced Micro Devices (AMD) and Netflix (NFLX). Company Calendar Last Earnings8/08/2024Ex-Dividend for 9/13 Dividend8/16/2024Dividend Payable9/13/2024Today9/23/2024Next Earnings (Estimated)11/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorFinance Industry Pharmaceutical preparations Sub-IndustryPharmaceuticals Current SymbolNASDAQ:RPRX CUSIP76028H20 CIK897075 Webwww.royaltypharma.com Phone212-883-0200FaxN/AEmployees80Year Founded1996Price Target and Rating Average Stock Price Target$42.00 High Stock Price Target$51.00 Low Stock Price Target$28.00 Potential Upside/Downside+52.5%Consensus RatingModerate Buy Rating Score (0-4)2.80 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)$1.34 Trailing P/E Ratio20.55 Forward P/E Ratio6.82 P/E Growth4.17Net Income$1.13 billion Net Margins30.08% Pretax Margin46.03% Return on Equity23.61% Return on Assets14.05% Debt Debt-to-Equity Ratio0.78 Current Ratio9.35 Quick Ratio9.35 Sales & Book Value Annual Sales$2.24 billion Price / Sales7.35 Cash Flow$4.45 per share Price / Cash Flow6.19 Book Value$16.88 per share Price / Book1.63Miscellaneous Outstanding Shares597,437,000Free Float484,521,000Market Cap$16.45 billion OptionableOptionable Beta0.46 Social Links This page (NASDAQ:RPRX) was last updated on 9/23/2024 by MarketBeat.com Staff From Our PartnersThe election trade you can't losePolitics is an unpredictable game. But no matter what happens in the next few months... There's one thin...Investors Alley | SponsoredHow the US Will Win the Great Lithium RaceChina spent $60B+ on lithium infrastructure in the past decade. It possesses 7.9% of the world’s supply, but i...DealMaker | Sponsored[SHOCKING] Crypto Document Leak…A shocking leak has revealed Japanese electronics giant Sony is now starting its own blockchain. This move ...Crypto 101 Media | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | Sponsored44-year Wall Street Vet: “Permanent devastation is coming to America”After 44 years on Wall Street, I've seen it all... Black Monday, the Great Recession, the Covid crash. B...InvestorPlace | Sponsored625,000% GainThe recent pullback in the crypto markets has left many investors in full-on panic mode, convinced the bull ru...Crypto Swap Profits | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | SponsoredWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | Sponsored Adding Choose a watchlist: Watchlist My Default Watchlist Adding Royalty Pharma plc You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Please log in to your account or sign up in order to add this asset to your watchlist. Share Royalty Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.